Clinical Trial Update: Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating OPB-31121 in relapsed or refractory Non-Hodgkin's Lymphoma and Multiple Myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• OPB-31121 (OPB-31121)

Snippet

Sponsor: Otsuka Beijing Research Institute | Conditions: Non-Hodgkin's Lymphoma(NHL), Multiple Myeloma | Phase 1 | Status: COMPLETED